enGene Holdings to Participate in Multiple Investor Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy ENGN?
Source: Yahoo Finance
- Investor Conference Schedule: enGene Holdings will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, showcasing its advancements in gene therapy, which is expected to attract investor interest and enhance the company's visibility.
- Timing and Format: The company will also participate in fireside chats at the Leerink Partners Global Healthcare Conference on March 9 and the Barclays Global Healthcare Conference on March 10, scheduled for 8:00 AM and 9:00 AM respectively, aiming to engage in deeper discussions with investors to bolster market confidence.
- Product Development Progress: enGene's lead program, detalimogene voraplasmid, is currently in the ongoing LEGEND Phase 2 trial focusing on treating patients with Non-Muscle Invasive Bladder Cancer, demonstrating the company's potential in addressing high clinical need diseases, which may lay the groundwork for future market performance.
- Platform Technology Advantage: The product utilizes enGene's proprietary DDX platform, which enables effective penetration of mucosal tissues and delivery of various therapeutic payloads, enhancing the company's competitiveness in the gene therapy sector and is expected to drive future product line expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENGN
Wall Street analysts forecast ENGN stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.960
Low
10.00
Averages
23.88
High
33.00
Current: 6.960
Low
10.00
Averages
23.88
High
33.00
About ENGN
enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Global Oncology Market Set for Rapid Growth
- Market Size Forecast: The global oncology market is projected to reach $279.98 billion in 2026 and grow to $748.17 billion by 2035, indicating a structural shift from single-agent treatments to combination therapies and next-generation cell therapies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to expand from $65.22 billion in 2025 to $170.19 billion by 2032, as approvals of combination therapies convert previously resistant tumors into viable treatment targets, driving market demand.
- Oncolytics Biotech New Data: Oncolytics Biotech will present new data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can make tumors more susceptible to immunotherapy, particularly showing positive results in breast and gastrointestinal cancer trials.
- Clinical Trial Progress: Oncolytics' REO 033 trial demonstrated a total survival of 27 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, with the FDA granting Fast Track Designation, which is expected to enhance the company's position in high-value markets.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is valued at $279.98 billion in 2026 and is projected to reach $748.17 billion by 2035, indicating a strong trend towards a shift from single-agent treatments to combination platforms and next-generation cell therapies, potentially creating significant market opportunities for related companies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, as the approval of combination therapies transforms previously resistant tumors into viable treatment targets, driving rapid industry growth.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can enhance tumor sensitivity to immunotherapy, potentially providing crucial scientific support for the company in a competitive market.
- Clinical Trial Progress: Oncolytics' REO 033 trial for KRAS-mutant metastatic colorectal cancer shows an overall survival of 27 months and a 33% objective response rate, with the FDA granting Fast Track Designation, which is expected to create significant market opportunities for the company.
See More
ENGENE HOLDINGS INC.: OPPENHEIMER LOWERS TARGET PRICE FROM $33 TO $30
Company Overview: Engene Holdings Inc. is a company involved in various business activities, including investments and holdings.
Target Price Adjustment: Oppenheimer has reduced the target price for Engene Holdings from $33 to $30.
See More
enGene Holdings Q1 Financial Highlights
- Earnings Performance: enGene Holdings reported a Q1 GAAP EPS of $0.44, indicating stable profitability despite competitive market pressures.
- Cash Position: As of January 31, 2026, the company held $312.5 million in cash, cash equivalents, and marketable securities, providing ample funding for future investments and operations.
- Operating Expense Increase: Operating expenses for Q1 2026 totaled $31.2 million, a 17.3% increase from $26.6 million in 2025, reflecting ongoing investments in R&D and market expansion.
- Positive Market Reaction: enGene Holdings saw a 14% surge in stock price on Friday, indicating investor optimism regarding the company's future prospects, particularly with major catalysts on the horizon.
See More
enGene Holdings to Participate in Multiple Investor Conferences
- Investor Conference Schedule: enGene Holdings will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, showcasing its advancements in gene therapy, which is expected to attract investor interest and enhance the company's visibility.
- Timing and Format: The company will also participate in fireside chats at the Leerink Partners Global Healthcare Conference on March 9 and the Barclays Global Healthcare Conference on March 10, scheduled for 8:00 AM and 9:00 AM respectively, aiming to engage in deeper discussions with investors to bolster market confidence.
- Product Development Progress: enGene's lead program, detalimogene voraplasmid, is currently in the ongoing LEGEND Phase 2 trial focusing on treating patients with Non-Muscle Invasive Bladder Cancer, demonstrating the company's potential in addressing high clinical need diseases, which may lay the groundwork for future market performance.
- Platform Technology Advantage: The product utilizes enGene's proprietary DDX platform, which enables effective penetration of mucosal tissues and delivery of various therapeutic payloads, enhancing the company's competitiveness in the gene therapy sector and is expected to drive future product line expansion.
See More
EnGene Files Shelf Registration for Up to $40 Million
- Funding Initiative: EnGene filed a shelf registration statement late Thursday for a potential sale of up to $40 million, aiming to provide flexibility for future capital needs and enhance the company's financial stability.
- Market Reaction: This move may attract investor attention, particularly in the biotech sector, where enhanced funding capabilities are often viewed as a positive signal for a company's expansion in R&D and marketing.
- Strategic Implications: By establishing a funding channel, EnGene can more effectively respond to market changes and industry competition, thereby improving its competitiveness in the biopharmaceutical market.
- Future Outlook: The implementation of this funding plan will provide EnGene with the necessary financial support to drive product development and market expansion, further solidifying its position in the industry.
See More
Global Oncology Market Set for Rapid Growth
- Market Size Forecast: The global oncology market is projected to reach $279.98 billion in 2026 and grow to $748.17 billion by 2035, indicating a structural shift from single-agent treatments to combination therapies and next-generation cell therapies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to expand from $65.22 billion in 2025 to $170.19 billion by 2032, as approvals of combination therapies convert previously resistant tumors into viable treatment targets, driving market demand.
- Oncolytics Biotech New Data: Oncolytics Biotech will present new data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can make tumors more susceptible to immunotherapy, particularly showing positive results in breast and gastrointestinal cancer trials.
- Clinical Trial Progress: Oncolytics' REO 033 trial demonstrated a total survival of 27 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, with the FDA granting Fast Track Designation, which is expected to enhance the company's position in high-value markets.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is valued at $279.98 billion in 2026 and is projected to reach $748.17 billion by 2035, indicating a strong trend towards a shift from single-agent treatments to combination platforms and next-generation cell therapies, potentially creating significant market opportunities for related companies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, as the approval of combination therapies transforms previously resistant tumors into viable treatment targets, driving rapid industry growth.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can enhance tumor sensitivity to immunotherapy, potentially providing crucial scientific support for the company in a competitive market.
- Clinical Trial Progress: Oncolytics' REO 033 trial for KRAS-mutant metastatic colorectal cancer shows an overall survival of 27 months and a 33% objective response rate, with the FDA granting Fast Track Designation, which is expected to create significant market opportunities for the company.
See More
ENGENE HOLDINGS INC.: OPPENHEIMER LOWERS TARGET PRICE FROM $33 TO $30
Company Overview: Engene Holdings Inc. is a company involved in various business activities, including investments and holdings.
Target Price Adjustment: Oppenheimer has reduced the target price for Engene Holdings from $33 to $30.
See More
enGene Holdings Q1 Financial Highlights
- Earnings Performance: enGene Holdings reported a Q1 GAAP EPS of $0.44, indicating stable profitability despite competitive market pressures.
- Cash Position: As of January 31, 2026, the company held $312.5 million in cash, cash equivalents, and marketable securities, providing ample funding for future investments and operations.
- Operating Expense Increase: Operating expenses for Q1 2026 totaled $31.2 million, a 17.3% increase from $26.6 million in 2025, reflecting ongoing investments in R&D and market expansion.
- Positive Market Reaction: enGene Holdings saw a 14% surge in stock price on Friday, indicating investor optimism regarding the company's future prospects, particularly with major catalysts on the horizon.
See More
enGene Holdings to Participate in Multiple Investor Conferences
- Investor Conference Schedule: enGene Holdings will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, showcasing its advancements in gene therapy, which is expected to attract investor interest and enhance the company's visibility.
- Timing and Format: The company will also participate in fireside chats at the Leerink Partners Global Healthcare Conference on March 9 and the Barclays Global Healthcare Conference on March 10, scheduled for 8:00 AM and 9:00 AM respectively, aiming to engage in deeper discussions with investors to bolster market confidence.
- Product Development Progress: enGene's lead program, detalimogene voraplasmid, is currently in the ongoing LEGEND Phase 2 trial focusing on treating patients with Non-Muscle Invasive Bladder Cancer, demonstrating the company's potential in addressing high clinical need diseases, which may lay the groundwork for future market performance.
- Platform Technology Advantage: The product utilizes enGene's proprietary DDX platform, which enables effective penetration of mucosal tissues and delivery of various therapeutic payloads, enhancing the company's competitiveness in the gene therapy sector and is expected to drive future product line expansion.
See More
EnGene Files Shelf Registration for Up to $40 Million
- Funding Initiative: EnGene filed a shelf registration statement late Thursday for a potential sale of up to $40 million, aiming to provide flexibility for future capital needs and enhance the company's financial stability.
- Market Reaction: This move may attract investor attention, particularly in the biotech sector, where enhanced funding capabilities are often viewed as a positive signal for a company's expansion in R&D and marketing.
- Strategic Implications: By establishing a funding channel, EnGene can more effectively respond to market changes and industry competition, thereby improving its competitiveness in the biopharmaceutical market.
- Future Outlook: The implementation of this funding plan will provide EnGene with the necessary financial support to drive product development and market expansion, further solidifying its position in the industry.
See More
